The Patent Finder

B3AR Therapeutics, Inc.

9 patents currently held · Updated Nov 16, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Pharmaceutical Compositions and the Treatment of Overactive Bladder (US 10,350,182) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

PatentTitleStatus Expires Confidence
US 9,907,767Pharmaceutical Compositions and the Treatment of Overactive Bladder
In force
 · High confidence
In forceHigh confidence
US 10,350,182Pharmaceutical Compositions and the Treatment of Overactive Bladder
In force
 · High confidence
In forceHigh confidence
US 10,668,034Pharmaceutical Compositions and the Treatment of Overactive Bladder
In force
 · High confidence
In forceHigh confidence
US 8,642,661Pharmaceutical Combinations of BETA-3 Adrenergic Receptor Agonists and Muscarinic Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 9,522,129Pharmaceutical Combination
In force
 · High confidence
In forceHigh confidence
US 9,956,194Compositions and Methods of Using Modified Release Solabegron for Lower Urinary Tract Symptoms
In force
 · High confidence
In forceHigh confidence
US 10,751,311Compositions and Methods of Using Modified Release Solabegron for Lower Urinary Tract Symptoms
In force
 · High confidence
In forceHigh confidence
US 10,221,126Solabegron Zwitterion and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,844,004Solabegron Zwitterion and Uses Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 2 patents in force now held by others · 1 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited